DAVA Oncology

davaonc.com

Optimize the recruitment and retention of patients in cancer clinical trials through the use of physician-focused approaches. DAVA has a proven track record having completed more than 45 Phase I to III trials and over the past six years with an average accrual enhancement rate of 30-40%.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

SEVEN PHARMACEUTICAL STOCKS THAT STAND TO WIN BEYOND THE COVID-19 CHASE

InvestorPlace | July 15, 2020

news image

It’s easy to miss the forest for the trees in markets like this. Especially when it comes to pharmaceutical stocks. What I mean is that, in some sectors, there are great stocks that get overlooked because a few of them are working on event-driven issues, while others are creating long-term solutions to major trends. This is especially true in the pharmaceutical and biotech spaces right now. Maybe it’s because the Kentucky Derby was postponed, but people are betting on ...

Read More

Research, PHARMA TECH

ALLIANCE PHARMA OPENS STATE-OF-THE-ART BIOANALYTICAL LABORATORY IN BRISBANE

Alliance Pharma | December 08, 2022

news image

Alliance Pharma a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, has opened its new 20,000-square-foot bioanalytical laboratory, Alliance Pharma Pty, Ltd., in Brisbane, Australia. The new Australia facility, which the company announced plans for earlier this summer, includes an expansive lab to provide much-needed small and large molecule bioanalytical services for a region with limited choices for bioana...

Read More

Pharma Tech

LANTHEUS ACQUIRES CERVEAU TECHNOLOGIES

Lantheus | February 07, 2023

news image

On February 6, 2023, Lantheus Holdings, Inc. (Lantheus), a company dedicated to improving patient outcomes through radiotherapy, diagnostics, and AI solutions that help clinicians to Find, Fight, and Follow® diseases, announced the acquisition of Cerveau Technologies, Inc. (Cerveau). Cerveau's primary asset is MK-6240, which is a second-gen F 18-labeled positron emission tomography (PET) imaging agent that targets Tau tangles present in Alzheimer's disease. ...

Read More

Business Insights

NEURIMMUNE EXPANDS DRUG DISCOVERY COLLABORATION WITH ONO PHARMACEUTICAL IN THE FIELD OF NEURODEGENERATIVE DISEASES

Neurimmune | January 17, 2022

news image

Neurimmune AG today announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. The collaboration is focused on creating antibody drugs against new therapeutic targets in the field of neurodegenerative diseases utilizing Neurimmune's proprietary Reverse Translational Medicine™ technology platform, a unique antibody drug creation approach. In November 2017, Ono and Neurimmune signed a first drug discovery collabo...

Read More
news image

SEVEN PHARMACEUTICAL STOCKS THAT STAND TO WIN BEYOND THE COVID-19 CHASE

InvestorPlace | July 15, 2020

It’s easy to miss the forest for the trees in markets like this. Especially when it comes to pharmaceutical stocks. What I mean is that, in some sectors, there are great stocks that get overlooked because a few of them are working on event-driven issues, while others are creating long-term solutions to major trends. This is especially true in the pharmaceutical and biotech spaces right now. Maybe it’s because the Kentucky Derby was postponed, but people are betting on ...

Read More
news image

Research, PHARMA TECH

ALLIANCE PHARMA OPENS STATE-OF-THE-ART BIOANALYTICAL LABORATORY IN BRISBANE

Alliance Pharma | December 08, 2022

Alliance Pharma a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, has opened its new 20,000-square-foot bioanalytical laboratory, Alliance Pharma Pty, Ltd., in Brisbane, Australia. The new Australia facility, which the company announced plans for earlier this summer, includes an expansive lab to provide much-needed small and large molecule bioanalytical services for a region with limited choices for bioana...

Read More
news image

Pharma Tech

LANTHEUS ACQUIRES CERVEAU TECHNOLOGIES

Lantheus | February 07, 2023

On February 6, 2023, Lantheus Holdings, Inc. (Lantheus), a company dedicated to improving patient outcomes through radiotherapy, diagnostics, and AI solutions that help clinicians to Find, Fight, and Follow® diseases, announced the acquisition of Cerveau Technologies, Inc. (Cerveau). Cerveau's primary asset is MK-6240, which is a second-gen F 18-labeled positron emission tomography (PET) imaging agent that targets Tau tangles present in Alzheimer's disease. ...

Read More
news image

Business Insights

NEURIMMUNE EXPANDS DRUG DISCOVERY COLLABORATION WITH ONO PHARMACEUTICAL IN THE FIELD OF NEURODEGENERATIVE DISEASES

Neurimmune | January 17, 2022

Neurimmune AG today announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. The collaboration is focused on creating antibody drugs against new therapeutic targets in the field of neurodegenerative diseases utilizing Neurimmune's proprietary Reverse Translational Medicine™ technology platform, a unique antibody drug creation approach. In November 2017, Ono and Neurimmune signed a first drug discovery collabo...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us